All In Biotech

NDA 217759 · Pharming

Joenja

Leniolisib Phosphate · Oral

NovelPriority reviewOrphan

CDER novel approval, Mar 24, 2023: To treat activated phosphoinositide 3-kinase delta syndrome

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Mar 24, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

9

5 Phase 3, 1 recruiting

FAERS reports

937

177 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 30, 2026.

JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 4 years of age and older who weigh 27 kg or greater. ( 1 ) JOENJA is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 4 years of age and older who weigh 27 kg or greater.

Mechanism: Leniolisib inhibits PI3K-delta by blocking the active binding site of PI3K-delta. In cell-free isolated enzyme assays, leniolisib was selective for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAkt pathway activity and inhibited proliferation and activation of B and T cell subsets. Gain-of-function variants in the gene encoding the p110-delta catalytic subunit or loss of function variants in the gene encoding the p85-alpha regulatory subunit each cause hyperactivity of PI3K-delta....

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 11, 2026 Supplement 6 · Efficacy · priority review OrphanLetterLabel
  • Mar 24, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
  • JOENJA · LENIOLISIB PHOSPHATE EQ 40MG BASE · TABLET, ORAL · Prescription
  • JOENJA · LENIOLISIB PHOSPHATE EQ 50MG BASE · TABLET, ORAL · Prescription
  • JOENJA · LENIOLISIB PHOSPHATE EQ 70MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Leniolisib" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • infection153
  • product dose omission issue133
  • off label use67
  • sinusitis63
  • headache47
  • nasopharyngitis44
  • fatigue32
  • ear infection29
  • pneumonia29
  • diarrhoea27
  • nausea24
  • alopecia23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20221
2023128
2024222
2025290
2026295

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Joenja (Leniolisib Phosphate)

2024 spending

$3.9M

Beneficiaries

n/a

81 claims

Per beneficiary

n/a

$803.08 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$2,256,027
2024$3,902,966

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Pharming

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.